GlassScriptPhysician profile
Tanisha Arora
NPI 1588898951
$753.10
in general payments reported to CMS, 2019-2025
15 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.89 · 2021: $32.32 · 2022: $163 · 2023: $172 · 2024: $195 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.54 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.76 | 2023-2025 | Teflaro, Dalvance |
| Astrazeneca Pharmaceuticals LP | $124.70 | 2022 | |
| Pfizer INC. | $48.55 | 2022-2024 | |
| Abbott Laboratories | $36.00 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $31.45 | 2020 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Merck Sharp & Dohme LLC | $18.35 | 2023 | Zerbaxa, Dificid, Recarbrio |
| Janssen Pharmaceuticals, INC | $18.25 | 2023 | Xarelto |
| Gilead Sciences, INC. | $18.02 | 2025 | Veklury |
| Baxter Healthcare | $17.43 | 2023 | Starling System |
| Kestra Medical Technology Services, INC. | $16.27 | 2024 | Assure Wcd |
| Grifols USA, LLC | $14.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2021 | |
| Nabriva Therapeutics, Plc | $11.44 | 2020 | |
| Rare Disease Therapeutics, INC. | $9.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanisha Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.